New Lab-on-a-Chip Method Predicts How Peptide Drugs Behave After Subcutaneous Injection | Research

The takeaway

A microfluidic system using hyaluronic acid microgel networks accurately predicted subcutaneous absorption rates for multiple peptide drugs, matching real-world human pharmacokinetic data.

7 peptide drugs validated
The microfluidic system correctly ranked absorption speed for seven different peptide drugs, matching published human pharmacokinetic data

What the researchers found

The microfluidics interaction study (MIS) method correctly ranked peptide drugs by their subcutaneous absorption rate constants, matching in vivo human data, and distinguished between electrostatic HA-binding and non-electrostatic aggregation mechanisms.

Why it matters

Developing peptide drugs for subcutaneous injection currently requires extensive animal testing because no good lab test predicts absorption. This microfluidic method could dramatically speed up drug development and reduce animal testing by providing accurate early-stage predictions.

The numbers in context

The system was validated against multiple peptide drugs with known in vivo absorption profiles.

How the study worked

A microfluidic system with polyelectrolyte microgel networks responsive to charged peptides was used to measure interaction strength with hyaluronic acid, aggregation tendency, and transport properties for seven peptide drugs. Results were compared with the commercial SCISSOR system and published in vivo absorption data.

Who was studied

In vitro testing of multiple peptide drugs

What this study cannot tell us

The system mimics HA interactions but doesn't capture blood flow, lymphatic drainage, immune cell interactions, or the full complexity of subcutaneous tissue. Validated against a limited set of peptide drugs — broader validation needed. The proposed charge-based mechanism for absorption rate differences needs further confirmation.

How to read the evidence

Preliminary but promising evidence from a well-designed methods development study. The correlation with human in vivo data strengthens confidence, but broader validation with more drugs and independent labs is needed.

When this study was published

Published in 2024, representing cutting-edge drug delivery research methodology for the rapidly growing peptide therapeutics field.

The bigger picture

Most biopharmaceuticals require subcutaneous injection, yet predicting how they'll absorb has been largely guesswork until clinical trials. This tool fills a critical gap in the drug development pipeline, potentially saving years and millions in development costs for the growing class of peptide therapeutics.

Questions still open

Could this system be adapted to predict absorption for larger proteins and antibodies, not just peptides?
How well does it predict absorption variability between patients with different body compositions?
Could formulation scientists use this tool to optimize peptide drug delivery by adjusting charge or aggregation properties?

Common questions

Why is it so hard to predict how injected peptide drugs absorb?

When you inject a peptide drug under the skin, it doesn't just flow into the bloodstream. It has to navigate through a complex gel-like matrix containing hyaluronic acid and other molecules. The peptide can stick to this matrix, clump together, or get taken up by lymph vessels instead of blood vessels. Each peptide interacts differently with this environment based on its charge, size, and tendency to aggregate — making absorption hard to predict without actually testing in living systems.

Could this technology make peptide drugs cheaper or faster to develop?

Potentially, yes. Currently, drug companies need extensive animal testing to understand subcutaneous absorption, which is expensive and time-consuming. A reliable lab test that predicts absorption early in development could eliminate many failed candidates before they reach expensive animal and clinical trials, saving both time and money.

Read the original research

A microfluidic in vitro method predicting the fate of peptide drugs after subcutaneous administration.

International journal of pharmaceutics, 667(Pt A), 124849

View on PubMed ↗Publisher’s paper ↗

Citation

Wanselius, Marcus; Abrahmsén-Alami, Susanna; Hanafy, Belal I; Mazza, Mariarosa; Hansson, Per. (2024). A microfluidic in vitro method predicting the fate of peptide drugs after subcutaneous administration.. International journal of pharmaceutics, 667(Pt A), 124849. https://doi.org/10.1016/j.ijpharm.2024.124849